FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/08/020565 [Registered on: 06/08/2019] Trial Registered Prospectively
Last Modified On: 29/06/2021
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Single Arm Study 
Public Title of Study   Patterns of recovery following sudden kidney failure  
Scientific Title of Study   Tubular recovery and renal reserve in AKI patients requiring dialysis 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Priyamvada P S 
Designation  Additional Professor 
Affiliation  Jawaharlal Institute of postgraduate Medical Education & Research 
Address  Dept of Nephrology Superspeciality Block
Jawaharlal Institute of postgraduate Medical Education and Research Dhanwantari Nagar
Pondicherry
PONDICHERRY
605006
India 
Phone  7598566984  
Fax  04132297317  
Email  priyamvadaps@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Priyamvada P S 
Designation  Additional Professor 
Affiliation  Jawaharlal Institute of postgraduate Medical Education & Research 
Address  Dept of Nephrology Superspeciality Block
Jawaharlal Institute of postgraduate Medical Education and Research Dhanwantari Nagar
Pondicherry
PONDICHERRY
605006
India 
Phone  7598566984  
Fax  04132297317  
Email  priyamvadaps@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Sejpal Kapil Navin 
Designation  Senior Resident 
Affiliation  Jawaharlal Institute of postgraduate Medical Education & Research 
Address  Dept of Nephrology Superspeciality Block
Jawaharlal Institute of postgraduate Medical Education and Research Dhanwantari Nagar
Pondicherry
PONDICHERRY
605006
India 
Phone  7598566984  
Fax  04132297317  
Email  kapilsejpal@gmail.com  
 
Source of Monetary or Material Support  
Jawaharlal Institute of postgraduate Medical Education and Research, Dhanwantari Nagar , Puducherry 605006 
 
Primary Sponsor  
Name  Jawaharlal Institute of postgraduate Medical Education Research 
Address  Dhawantari Nagar 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Priyamvada P S  JIPMER  Room no 5325, Superspeciality block DEPARTMENT OF NEPHROLOGY JIPMER
Pondicherry
PONDICHERRY 
7598566984

priyamvadaps@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute Ethics Committe JIPMER  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N170||Acute kidney failure with tubularnecrosis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Amino acid infusion to assess the renal reserve   Aminoacid infusion (10%) will be given at the rate of 4 ml/KBW over a period of 3 hours in patients who have a normal e GFR and uACR , 3 months after Acute Kidney Injury 
Comparator Agent  There will not be any comparator arm  not applicable  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  All dialysis requiring patients with AKI (defined as more than or equal to 1.5 times increase in the baseline creatinine within 7 days or more than or equal to 0.3mg/dl increase from the baseline creatinine within 48hours or urine output of less than 0.5ml/kg/hr for 6 hours )  
 
ExclusionCriteria 
Details  1. CKD stage 5d (eGFR<15ml/min)
2. Obstructive uropathy 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1. To assess the tubular recovery in patents with dialysis requiring AKI with urinary TIMP2(Tubular inhibitor of metalloproteinase 2) and IGFBP-7(Insulin like growth factor binding protein-7) as candidate markers
2. To assess the renal reserve in patients who show a complete recovery of AKI (eGFR60ml/min and uACR of 30 at 3 months after the onset of AKI)
 
Outcomes will be assessed at 3 months from onset of Acute Kidney Injury 
 
Secondary Outcome  
Outcome  TimePoints 
To correlate the renal injury markers and renal reserve with eGFR at 1 year following AKI  One year 
 
Target Sample Size   Total Sample Size="232"
Sample Size from India="232" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/09/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   Not applicable  
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  
Introduction
Acute Kidney Injury (AKI)can lead to Chronic Kidney Disease(CKD) in future . The current screening recommendations to identify the the AKI to CKD include periodic assement of urine albumin excretion(uACR),  glomerular filtration rate(e GFR)  and blood pressure . These investigations are not sensitive enough to detect subclinical persistent damage, which might act as a forerunner of CKD. An accurate and sensitive marker to assess the extent of tubular damage would aid in the risk stratification, especially in individuals who lack the conventional risk factors.Data on utility of urine biomarkers and renal reserve to identify persistent kidney damage following AKI is limited. 

Procedure 

All the dialysis requiring AKI patients , who satisfies the inclusion and exclusion criteria will be recruited for the study. At one 2 weeks and 3 months after  the onset of AKI ,  eGFR  and uACR will be measured .The eGFR will be calculated using the CKD-EPI formula.  Urine samples will be collected for  TIMP-2 and IGFBP-7 and will be preserved at -40 degree C . The analysis for this markers will be done at a later date using Enzyme Linked Immunosorbent Assay.  At 3 months from the onset of AKI ,for patients who show complete recovery,( Defined as eGFR>60ml/min and uACR<30) renal reserve will be assessed by  a Technetium-99m  Diethylene Triamine PentaAcetic acid(Tc-99m DTPA ) scan the following method.

DTPA GFR measurement protocol:

Technetium-99m (Tc-99m) DTPA (Diethylene Triamine PentaAcetic acid) will be prepared from DTPA cold kit as per the recommended protocol of the manufacturer (BRIT, Mumbai). Radiochemical purity of the labelled Tc-99m DTPA will be measured by paper chromatography and should be more than 95%.1 mCi of Tc-99m DTPA in approximately 0.5 - 1 ml will be loaded in syringe using sterile precautions. The weight of the loaded radiopharmaceutical will be measured using a microbalance (Model: FGB 220, Wensar, Mumbai). A standard syringe containing similar amount of activity will be prepared, weighed and set aside.

Baseline GFR measurement:

On the first day, 1 mCi of Tc-99m DTPA will be injected intravenously into the participant who is positioned supine on gamma camera (Symbia T6, Siemens or Discovery NM630, GE Healthcare). Two venous blood samples of about 3 ml will be withdrawn into separate anti coagulated vials at 60 and 180 minutes after injection from a site different from injection. The samples will be allowed to stand undisturbed for 24 hours so that plasma and cell components separate.

24 hours after injection, a standard solution will be prepared by dissolving the radio pharmaceutical in standard syringe in 1000 ml of water. 1 ml of standard solution, and 1 ml of plasma from each of the blood samples will be pipetted out using a micropipette.  The samples will be counted in a gamma counter (Wizard2, Perkin Elmer, USA) for 1 minute and repeated twice.GFR will be calculated by the Russell’s two sample slope intercept method and normalized for body surface area.

Stimulated GFR measurement:

On the second day, the same procedure will be repeated after infusion of amino acid 10 % aminoacid solution at the rate of 4 ml/KBW for 3  hoursRenal functional reserve will be calculated as percentage increase in GFR relative to baseline measurement. 

At 6 months follow up ,urinary ACR will be assessed and eGFR will be assessed using CKD-EPI formula. At 12 month follow up, again the urinary ACR and eGFR will be assessed and patients will also be assessed for a new onset hypertension.

Statistical Methods 

Sample size calculation

In  a  previous observational s,  study on  snake  bite  related  AKI from the same centre ,  35% patients at 6 months following AKI  had biomarker positivity in urine , with normal e GFR and u ACR .  There is no available data on renal reserve following AKI  from India .  Assuming  that  35%  of  the  patients  will  have biomarker  positivity,  it  would  require  to  recruit  179  patients  at  20%  relative precision  and  at  95%  confidence  .  Since  the  recruitment  happens  at  admission, assuming   30%  mortality for AKI,  a  total  number  of  232  patients  will  be recruited  for the study. 

Plan for data analysis

The distribution of categorical variables such as gender, BMI will be expressed in terms of frequency and percentages. The distribution of continuous variables such as blood pressure, age, eGFR and TIMP-2 levels will be expressed in terms of mean with standard deviation or median with interquantile range based on distribution of data. The comparison between the eGFR, urinary TIMP-2 and IGFBP-7 will be carried out by using paired t test or wilcoxan signed rank sum test. The changes in parameter between subgroup will be expressed in terms of repeated measure of ANOVA.



 
Close